Compare Gap Inc (GAP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Inovio Pharmaceuticals Inc — how do they compare? Gap Inc trades at $20.51 (market cap $7.30B), while Inovio Pharmaceuticals Inc trades at $1.13 (market cap $96.26M). The key difference: Gap Inc is far larger — about 75.8× Inovio Pharmaceuticals Inc's market cap, and Gap Inc pays a 3.45% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GAP | INO | |
|---|---|---|
Market Cap | $7.30B | $96.26M |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $2.87 |
52-Week Low | $18.35 | $1.05 |
Enterprise Value | $10.38B | $67.27M |
Dividend Yield | 3.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $20.65, up 2.58% today, with a bullish technical signal supported by oscillators and key resistance at $21. The stock shows strong fundamentals with a P/E of 8.05, net income margin of 6.25%, and consistent earnings beats in recent quarters. Revenue grew to $15.09B in 2025, and operating cash flow remains robust at $1.49B. Recent news highlights digital transformation efforts and a potential turnaround in the Athleta segment.
The outlook is positive with a consensus price target of $27.00, implying 30.7% upside, though risks include ongoing legal investigations and competitive pressures. Analyst sentiment is mixed with 39.58% buy ratings, but improving profitability and undervalued metrics support a constructive view for long-term investors.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
